Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy
Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy
复制标题
激活NK细胞的Fc融合蛋白用于肿瘤免疫治疗的研究进展
DOI：
10.1016/j.intimp.2022.108783
复制
发表时间：
2022-05-10
影响因子：
5.6
通讯作者：
Wei, Min-Jie
中科院分区：
文献类型：
--
作者：
Niu, Yan-Xin;Xu, Zhao-Xu;Wei, Min-Jie
随着生物工程技术的飞速发展，Fc融合蛋白作为一种新型的重组蛋白，在肿瘤治疗中具有广阔的应用前景。已经研究了许多相关的抗肿瘤Fc融合蛋白，并且处于不同的开发阶段。Fc融合蛋白通过将抗体的Fc区与功能性蛋白质或肽融合来构建。它们保留了后者的生物活性和前者的部分性质。这种结构和功能优势使得Fc融合蛋白成为肿瘤免疫治疗的有效工具，特别是用于募集和激活在肿瘤免疫治疗中起关键作用的自然杀伤（NK）细胞。尽管肿瘤细胞已经开发出规避NK细胞的细胞毒性作用或诱导缺陷型NK细胞的机制，但已证明Fc融合蛋白以不同方式有效激活NK细胞以杀死肿瘤细胞，例如抗体依赖性细胞介导的细胞毒性（ADCC），以不同方式激活NK细胞以促进杀死肿瘤细胞。本文就NK细胞免疫治疗肿瘤及Fc融合蛋白激活NK细胞抗肿瘤治疗的研究进展作一综述。
The rapid development of bioengineering technology has introduced Fc-fusion proteins, representing a novel kind of recombinant protein, as promising biopharmaceutical products in tumor therapy. Numerous related antitumor Fc-fusion proteins have been investigated and are in different stages of development. Fc-fusion proteins are constructed by fusing the Fc-region of the antibody with functional proteins or peptides. They retain the bioactivity of the latter and partial properties of the former. This structural and functional advantage makes Fcfusion proteins an effective tool in tumor immunotherapy, especially for the recruitment and activation of natural killer (NK) cells, which play a critical role in tumor immunotherapy. Even though tumor cells have developed mechanisms to circumvent the cytotoxic effect of NK cells or induce defective NK cells, Fc-fusion proteins have been proven to effectively activate NK cells to kill tumor cells in different ways, such as antibody-dependent cell-mediated cytotoxicity (ADCC), activate NK cells in different ways in order to promote killing of tumor cells. In this review, we focus on NK cell-based immunity for cancers and current research progress of the Fc-fusion proteins for anti-tumor therapy by activating NK cells.